Related Experiment Video
Updated: Jun 12, 2026
Germ Cell Transplantation and Testis Tissue Xenografting in Mice
Published on: February 6, 2012
Array comparative genomic hybridization analysis does not show genetic alterations in spermatozoa and offspring
E Goossens1, P de Vos, H Tournaye
1Biology of the Testis (BITE), Research Laboratory for Embryology and Genetics (EMGE), Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium. ellen.goossens@uzbrussel.be
Background:
The most promising procedure to restore fertility in male childhood cancer patients is spermatogonial stem cell transplantation (SSCT). Although the efficiency of SSCT has been proven in the mouse model, its safety needs to be investigated too before considering any implementation in the clinic. To examine the incidence of genetic abnormalities after SSCT, the karyotypes of donor-derived spermatozoa and offspring were analyzed.
Methods:
Donor cells were obtained from prepubertal mice and introduced in the seminiferous tubules of genetically sterile W/W(v) mice. Five to 10 months after SSCT, DNA was extracted from epididymal sperm to perform array comparative genomic hybridization (aCGH) analysis. In addition, spermatozoa, liver and kidney from the offspring were subjected to aCGH analysis.
Results:
Numerical chromosomal aberrations could not be detected in spermatozoa from transplanted males, nor in their offspring. The few genetic deviations (deletions, amplifications) observed were all polymorphisms.
Conclusions:
No major genetic alterations could be detected after SSCT. These data are supportive for further development of SSCT as a strategy for fertility restoration.
Insights
Spermatogonial stem cell transplantation (SSCT) shows promise for restoring fertility. This study found no major genetic abnormalities in donor-derived sperm or offspring after SSCT in mice, supporting its clinical safety.
Area of Science:
- Reproductive biology
- Genetics
- Oncology
Background:
- Spermatogonial stem cell transplantation (SSCT) is a leading fertility restoration method for male childhood cancer survivors.
- Clinical application of SSCT requires thorough safety evaluation, particularly regarding genetic integrity.
- Previous studies demonstrated SSCT efficiency in mouse models, but safety data is crucial.
Purpose of the Study:
- To assess the safety of SSCT by investigating genetic abnormalities in donor-derived sperm and offspring.
- To evaluate the incidence of chromosomal aberrations and other genetic alterations post-SSCT.
Main Methods:
- Donor spermatogonial stem cells were transplanted into genetically sterile W/W(v) mice.
- Array comparative genomic hybridization (aCGH) was used to analyze DNA from epididymal sperm (5-10 months post-transplant).
- aCGH analysis was also performed on sperm, liver, and kidney tissues from the offspring of transplanted mice.
Main Results:
- No numerical chromosomal aberrations were detected in spermatozoa from SSCT recipients.
- Offspring derived from SSCT also showed no numerical chromosomal aberrations.
- Minor genetic variations observed were identified as polymorphisms, not significant alterations.
Conclusions:
- Spermatogonial stem cell transplantation (SSCT) did not induce major genetic alterations in the analyzed samples.
- The findings support the safety of SSCT for fertility restoration in preclinical models.
- Further development of SSCT as a clinical fertility preservation strategy is warranted based on these results.
